Bone remodelling is a delicate homeostasis involving the regulation of both osteoblast and osteoclast activities. Maintenance of this balance helps prevent disorders such as rheumatoid arthritis, osteoporosis, and multiple myeloma-related bone loss. 1 In clinical practice, inflammatory bone loss remains difficult to treat, especially in complicated orthopedic trauma and arthroplasty cases. Inflammation of the skeletal system activates immune reactions and produces cytokines involved in osteoclast recruitment and differentiation, leading to excessive bone resorption. 2 However, an effective regimen for the treatment of inflammatory bone loss is lacking.
macrophage colony-stimulating factor (M-CSF). 3 Receptor activator of nuclear factor-κB ligand belongs to the tumour necrosis factor (TNF) superfamily; binding with its receptor, RANK, on the surface of osteoclast precursors recruits adaptor TNF receptor-associated factors (TRAFs). This process is important for osteoclast formation because it activates several downstream signalling pathways and the transcription factor activator protein 1 (AP-1), leading to full activation of T-cell cytoplasmic 1 (NFATc1). 4 The expression of NFATc1 modulates osteoclast differentiation and functions via the induction of osteoclast-specific genes, including those encoding dendritic cell-specific transmembrane protein (DC-STAMP), TRAP, cathepsin K, calcitonin receptor (CTR), and matrix metalloproteinase 9 (MMP-9). 5, 6 Natural products have been an increasingly important source for drug development. 7 We recently identified dehydrocostus lactone (DHE) as an effective inhibitor of osteoclastogenesis and osteoclast-related bone loss. Dehydrocostus lactone is a natural sesquiterpene lactone derived from the roots of Saussurea lappa, and it has been reported to have anti-inflammatory, anti-ulcer, anti-tumour, and immunomodulatory properties. 8, 9 However, the effect of DHE on osteoclast formation has not been reported. It has been shown that proinflammatory cytokines promote osteoclastogenesis, 10 and overactivation of osteoclast activity plays an essential part in the origin of bone homeostatic imbalances. 11 Thus, osteoclasts could be a key target in the treatment of inflammatory bone loss. Lipopolysaccharide (LPS) and titanium particles are both potent inducers of the immune system, and they play critical roles in the development of osteolytic bone loss. 12 The purpose of this study was therefore to investigate the effects of DHE on osteoclastogenesis and on murine models of LPS-induced bone loss and particle-induced calvarial osteolysis, and to characterize the underlying mechanism of these processes.
| MATERIAL S AND ME THODS

| Reagents and antibodies
Foetal bovine serum and Minimum Essential Medium Eagle Alpha
Modification (α-MEM) were obtained from Gibco (Sydney, Australia). 
| Cell culture and osteoclast differentiation
Primary murine bone monocyte/macrophage precursors were isolated from the unfractionated long bones of 6-week-old C57BL/6 mice and differentiated into bone marrow-derived macrophages (BMMs) in α-MEM containing 30 ng/mL of M-CSF for 3-4 days.
The cells were cultured in at 37°C in 5% CO 2 incubator, and the medium was changed every 2 days. The effect of DHE on BMM viability was determined using a CCK-8 assay. 
| Immunofluorescence staining
The effect of DHE on F-actin ring formation was visualized using rhodamine-phalloidin staining. Bone marrow-derived macrophages were plated into 96-well plates and treated with the indicated concentrations of DHE in the presence of 30 ng/mL of M-CSF and 100 ng/mL of RANKL for 5 days. The cells were then fixed in 4% paraformaldehyde at room temperature; and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline. F-actin was stained with rhodamine-phalloidin in 2% bovine serum albumin for 1 hour. The nuclei were stained with 4′,6-diamidino-2-phenylindole for 5 minutes. Fluorescence images were acquired using a Leica DMI4000B fluorescence microscope (Wetzlar, Germany). Three fields were randomly selected, and the numbers and sizes of the F-actin rings were calculated using Imagej (NIH).
| Bone resorption pit assay
The effects of DHE on osteolytic bone resorption in vitro were assessed on bone discs. An equal number of BMM-derived pre-osteoclasts were seeded onto bone discs and incubated overnight. The cells were then treated with or without 4 μmol/L DHE in osteoclastogenic medium for 2-3 days. The discs were fixed with 4% paraformaldehyde, and adhered cells were removed by gentle brushing. Three random views in each disc were visualized using a Hitachi S-3700N Scanning Electron Microscopy (Tokyo, Japan), and the resorbed areas were quantified by Imagej (NIH). 
| Quantitative polymerase chain reaction
| Western blot analysis
To investigate the effects of DHE on RANKL-induced signalling pathways, RAW264.7 cells were seeded into six-well plates at 8 × 10 
| Statistical analysis
Data are expressed as the mean ± SD. All experiments were independently carried out at least three times. Unpaired Student's t tests were used to compare two groups, and one-way ANOVA tests were used for ≥three groups, with SPSS for Windows, version 19.0 (IBM Crop., Armonk, NY). A value of P < 0.05 indicated a significant difference between groups.
| RE SULTS
| DHE inhibited the differentiation of BMMs into osteoclasts without cytotoxicity
The cytotoxicity of DHE ( Figure 1A ) toward osteoclast precursor cells was determined by the CCK-8 assay with a range of doses of DHE, and the results indicate that the IC 50 of DHE for BMMs was 17.5 μmol/L ( Figure 1B) .
To investigate the effect of DHE on osteoclast formation, BMMs were cul- 
| DHE suppressed RANKL-induced osteoclast marker gene expression
The anti-osteoclastogenic properties of DHE on the expression of tran- 
| DHE interfered with F-actin ring formation and bone resorption in vitro
The formation of F-actin rings is a prerequisite to the adhesion of osteoclasts to bone. To determine whether DHE impaired the for- 
| DHE attenuated RANKL-induced NF-κB signalling activation
The downstream pathways of RANK are important for osteoclast differentiation, so we determined whether DHE modulated the phosphorylation of MAPK and NF-κB after RANKL stimulation. The phosphorylation peaked within 60 minutes after RANKL stimulation ( Figure 4) . The phosphorylation of MAPK pathway was unaffected. RANKL-induced NF-κB activation is also crucial for osteoclast formation. As shown in Figure, activation of the upstream IKK complex, p65, and IκBα was suppressed by DHE.
Taken together, these results suggest that DHE inhibited osteoclast formation by modulating the RANKL-induced activation of NF-κB signalling.
| DHE impaired NFATc1 induction
NFATc1 is an expression inducer of osteoclast marker genes, and a master transcription factor during osteoclast formation. 13 To determine whether DHE attenuated the expression of NFATc1, we investigated protein expression in the presence of DHE during osteoclastogenesis of BMMs. Figure 5 shows that the expression of NFATc1 reached a peak at day 3, while its expression was significantly down-regulated in the presence of DHE. In addition, it attenuated the expression of cathepsin K and c-Src in BMMs during osteoclastogenesis ( Figure 5 ), which is critical for osteoclast formation and function. 
| D ISCUSS I ON
DHE is a naturally occurring sesquiterpene lactone reported to have many biological effects, including anticancer, bactericidal and antioxidative stress properties. 9, 14, 15 However, there has been no report examining the effects of DHE on osteoclasts. In this study, we investigated its effects on RANKL-induced osteoclast formation and function, and determined the underlying mechanism in vitro. We also examined its effects on LPS-induced bone loss and particle-induced calvarial osteolysis in vivo.
NFATc1 is a central regulator of the expression of marker genes, such as DC-STAMP, cathepsin K, CTR, TRAP, MMP-9 and V-ATPase a3 in the differentiation of precursors into functional osteoclasts.
In this study, we showed that treatment with DHE suppressed the mRNA expression of osteoclast marker genes, including those encoding NFATc1, DC-STAMP, cathepsin K, CTR, TRAP, MMP-9, V-ATPase a3, and OSCAR. An in vitro study also confirmed the inhibitory effects of DHE on F-actin ring formation, which is essential for bone resorption and osteoclast adhesion to bone. 
| CON CLUS ION
Our findings demonstrate that DHE attenuated RANKL-induced osteoclast formation and inhibited F-actin ring formation and bone resorption in vitro. Moreover, DHE partially restored LPS-induced bone loss in cancellous bone and particle-induced calvarial osteolysis in vivo. Its mechanism involved suppression of the expression of NFATc1 and other marker genes during osteoclast formation by targeting the activation of NF-κB signalling. These data suggest that DHE could be used for the treatment of osteoclast-related skeletal disorders.
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